Bernard D. Johnson

Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

Sridhar K. Rabindran, Carolyn Discafani, Edward Rosfjord et al. · Cancer Research · 2004 · 638 citations · Full text

Medicine, Oncology, Pharmacology +13

Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity

Hwei‐Ru Tsou, Elsebe G. Overbeek-Klumpers, William Hallett et al. · Journal of Medicinal Chemistry · 2005 · 299 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity

Hwei‐Ru Tsou, Nellie Mamuya, Bernard D. Johnson et al. · Journal of Medicinal Chemistry · 2001 · 274 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)

Allan Wissner, Elsebe Overbeek, Marvin F. Reich et al. · Journal of Medicinal Chemistry · 2002 · 266 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Genetic Variation in OAS1 Is a Risk Factor for Initial Infection with West Nile Virus in Man

Jean K. Lim, Andrea Lisco, David H. McDermott et al. · PLoS Pathogens · 2009 · 242 citations · Full text

Life Sciences, Infectious Diseases, Molecular Genetics +16